Updated:
The Copernicus Group IRB
The Copernicus Group IRB was founded in Durham, North Carolina, and serves as an independent institutional review board for clinical trials.
The Copernicus Group IRB
The Copernicus Group IRB was founded in Durham, North Carolina, and serves as an independent institutional review board for clinical trials. Its core function is ethical oversight: reviewing study protocols, informed consent documents, and safety data to protect human subjects in biomedical research, a role mandated by the U.S. Department of Health and Human Services under 45 CFR 46. The firm focuses on the healthcare services sector, serving pharmaceutical, biotech, and medical device companies that outsource IRB review for operational efficiency and regulatory compliance. As an IRB organization, the Copernicus Group does not deploy capital or pursue investment returns. Its revenue derives from review fees charged to sponsors, and its operational footprint is concentrated in the United States, with Durham as the primary base. The firm handles a range of trial types, including multi-site studies and emergency-use protocols, but public information on the number of staff or active reviews is limited. The business model aligns with the broader trend of for-profit, centralized IRBs competing with academic and non-profit boards. The Copernicus Group lacks a disclosed founder, team size, or parent entity in public records as of mid-2026. It does not maintain a publicly accessible website, LinkedIn profile, or media presence beyond standard regulatory filings. This opacity is unusual for an IRB, which typically seeks visibility to reassure sponsors and regulators of its credentials. The firm's structural differentiator, if any, remains opaque due to sparse disclosure. It likely operates as a for-profit private entity, possibly part of a larger healthcare services group, but no ownership structure is publicly confirmed. Without a visible governance framework or published roster, its market position among IRBs — such as Western IRB, Advarra, or the WCG Group — cannot be assessed.
General information
Firm type
other
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Durham
Corporate office
Durham, NC, United States
Sector focus
Frequently asked questions
What is the primary function of The Copernicus Group IRB?
The Copernicus Group IRB serves as an institutional review board (IRB) for clinical trials, reviewing study protocols, consent forms, and safety data to ensure ethical treatment of human subjects. This role is required by U.S. federal regulations (45 CFR 46) for federally funded or FDA-regulated research. The firm operates as an independent, for-profit ethics committee.
Is The Copernicus Group IRB affiliated with any parent organization?
Public records do not identify a parent company or ownership structure for The Copernicus Group IRB as of mid-2026. It may be a standalone entity or part of a larger healthcare services conglomerate, but no affiliation has been disclosed in regulatory filings or press releases.
How does The Copernicus Group IRB differ from academic IRBs?
The Copernicus Group is a for-profit, centralized IRB, unlike academic committees that are institution-based. Centralized IRBs review studies from multiple sponsors, offering faster turnaround and standardized processes. This model is increasingly used by pharmaceutical companies for multi-site trials, though critics note potential conflicts of interest in for-profit ethics review.
What types of clinical trials does The Copernicus Group IRB review?
The firm likely reviews a range of biomedical studies, including drug, device, and biologic trials, though specific trial types are not publicly detailed. As a commercial IRB, it typically handles protocols from pharmaceutical and biotech sponsors across various therapeutic areas, from Phase I through post-market studies.
Does The Copernicus Group IRB operate internationally?
There is no public evidence that The Copernicus Group IRB conducts reviews outside the United States. Its headquarters in Durham, North Carolina, suggests a domestic focus, though U.S. IRBs can oversee multi-site international trials if the sponsor complies with local regulations.
What regulatory standards must The Copernicus Group IRB follow?
IRBs in the U.S. must comply with the Common Rule (45 CFR 46) and FDA regulations (21 CFR 50, 56). The Copernicus Group must register with the Department of Health and Human Services and adhere to Good Clinical Practice (GCP) guidelines. Enforcement is conducted by the FDA and the Office for Human Research Protections (OHRP).
Why is there limited public information about The Copernicus Group IRB?
The firm maintains a low public profile with no accessible website, LinkedIn presence, or media coverage. This is unusual for an IRB, as sponsors and regulators expect transparency. The lack of disclosure may indicate a small operation or a strategic decision to avoid public scrutiny.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: